Recently, it has been stated that Smads play an active role in all conditions where transforming growth factor-beta (TGF-β) is involved, including periodontal inflammation. This study aimed to examine the levels of TGF-β and inhibitor Smads in saliva and gingival crevicular fluid (GCF) in patients with Stage 3 Grade B periodontitis before and after non-surgical periodontal treatment. Twenty (20) stage 3 grade B periodontitis and 20 periodontally healthy individuals were included in the study. Clinical periodontal measurements were recorded; periodontitis patients received non-surgical periodontal treatment, and GCF and saliva samples were obtained at baseline and one month after treatment. TGF-β, Smad6, and Smad7 were determined by ELISA.

Inclusion Criteria:

• Have at least 20 natural teeth, excluding third molars.
• Periodontitis patients had at least two non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm with gingival inflammation, and alveolar bone loss affecting >30% of the teeth, as detected on clinical and radiographical examinations.
• Periodontally healthy control group had no sign of gingival inflammation, no PD > 3mm and no evidence of attachment or bone loss

Exclusion Criteria:

• History of systemic disease.
• Regular use of any drugs which can effect the immune system or inflammatory response in the 6 months preceding the start of the study.
• Periodontal treatment during last 6 months that could affect periodontal status.
• Smoking.
• History of radiotherapy or chemotherapy.
• Current pregnancy, lactation or menopause.

1. group (Control): Periodontally and systemically healthy
2. group: Systemically healthy and periodontitis